Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance

Diabetes. 2013 May;62(5):1709-17. doi: 10.2337/db12-1042. Epub 2013 Jan 17.

Abstract

Fish oils (FOs) have anti-inflammatory effects and lower serum triglycerides. This study examined adipose and muscle inflammatory markers after treatment of humans with FOs and measured the effects of ω-3 fatty acids on adipocytes and macrophages in vitro. Insulin-resistant, nondiabetic subjects were treated with Omega-3-Acid Ethyl Esters (4 g/day) or placebo for 12 weeks. Plasma macrophage chemoattractant protein 1 (MCP-1) levels were reduced by FO, but the levels of other cytokines were unchanged. The adipose (but not muscle) of FO-treated subjects demonstrated a decrease in macrophages, a decrease in MCP-1, and an increase in capillaries, and subjects with the most macrophages demonstrated the greatest response to treatment. Adipose and muscle ω-3 fatty acid content increased after treatment; however, there was no change in insulin sensitivity or adiponectin. In vitro, M1-polarized macrophages expressed high levels of MCP-1. The addition of ω-3 fatty acids reduced MCP-1 expression with no effect on TNF-α. In addition, ω-3 fatty acids suppressed the upregulation of adipocyte MCP-1 that occurred when adipocytes were cocultured with macrophages. Thus, FO reduced adipose macrophages, increased capillaries, and reduced MCP-1 expression in insulin-resistant humans and in macrophages and adipocytes in vitro; however, there was no measureable effect on insulin sensitivity.

Trial registration: ClinicalTrials.gov NCT00579436.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Fat / blood supply
  • Abdominal Fat / immunology*
  • Abdominal Fat / metabolism
  • Abdominal Fat / pathology
  • Angiogenesis Inducing Agents / metabolism
  • Angiogenesis Inducing Agents / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / metabolism
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Body Mass Index
  • Capillaries / immunology
  • Capillaries / metabolism
  • Capillaries / pathology
  • Cells, Cultured
  • Chemokine CCL2 / blood
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism
  • Coculture Techniques
  • Dietary Supplements*
  • Docosahexaenoic Acids
  • Down-Regulation
  • Drug Combinations
  • Eicosapentaenoic Acid
  • Fatty Acids, Omega-3 / metabolism
  • Fatty Acids, Omega-3 / therapeutic use*
  • Female
  • Fish Oils / therapeutic use
  • Humans
  • Insulin Resistance*
  • Macrophages / immunology*
  • Macrophages / metabolism
  • Macrophages / pathology
  • Male
  • Metabolic Syndrome / complications
  • Metabolic Syndrome / diet therapy*
  • Metabolic Syndrome / immunology
  • Metabolic Syndrome / metabolism
  • Middle Aged
  • Muscles / immunology
  • Muscles / metabolism
  • Muscles / pathology
  • Obesity / complications*
  • RNA, Messenger / metabolism

Substances

  • Angiogenesis Inducing Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • CCL2 protein, human
  • Chemokine CCL2
  • Drug Combinations
  • Fatty Acids, Omega-3
  • Fish Oils
  • RNA, Messenger
  • Docosahexaenoic Acids
  • Eicosapentaenoic Acid
  • Omacor

Associated data

  • ClinicalTrials.gov/NCT00579436